Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher B Granger

Showing results (271-280 of 910) with videos related to

Pageof 91
Sort By:
JAMA|February 26, 2020
Major Adverse Cardiovascular Events After 12 Months Among Patients With Acute Coronary Syndrome Receiving Loading Doses of Atorvastatin Prior to Planned PCIRenato D Lopes, Pedro G M de Barros E Silva, Lucas Petri Damiani, et al.
European Heart Journal. Acute Cardiovascular Care|March 3, 2020
Acute Cardiovascular Care Association position statement for the diagnosis and treatment of patients with acute myocardial infarction complicated by cardiogenic shock: A document of the Acute Cardiovascular Care Association of the European Society of CardiologyUwe Zeymer, Hector Bueno, Christopher B Granger, et al.
Journal of the American College of Cardiology|March 21, 2020
Oral Anticoagulation and Cardiovascular Outcomes in Patients With Atrial Fibrillation and End-Stage Renal DiseaseSean D Pokorney, Eric Black-Maier, Anne S Hellkamp, et al.
American Heart Journal|December 9, 2019
High-throughput targeted proteomics discovery approach and spontaneous reperfusion in ST-segment elevation myocardial infarctionJay S Shavadia, Christopher B Granger, Wendimagegn Alemayehu, et al.
American Heart Journal|November 2, 2013
Prognostic implications of left ventricular end-diastolic pressure during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Findings from the Assessment of Pexelizumab in Acute Myocardial Infarction studyAkshay Bagai, Paul W Armstrong, Amanda Stebbins, et al.
Circulation|December 8, 2004
Lessons learned from a clinical trialPaul W Armstrong, L Kristin Newby, Christopher B Granger, et al.
American Heart Journal|May 22, 2012
Variations in practice and outcomes in patients undergoing primary percutaneous coronary intervention in the United States and Canada: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI) trialRajendra H Mehta, Padma Kaul, Renato D Lopes, et al.
European Journal of Heart Failure|October 31, 2009
Adherence to medication according to sex and age in the CHARM programmeBradi B Granger, Inger Ekman, Christopher B Granger, et al.
JAMA|January 4, 2007
Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial, Paul W Armstrong, Christopher B Granger, et al.
Circulation|April 1, 2020
Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUSJohn H Alexander, Daniel Wojdyla, Amit N Vora, et al.
Pageof 91

Showing results (271-280 of 910) with videos related to

Sort By:
Pageof 91
JAMA|February 26, 2020
Major Adverse Cardiovascular Events After 12 Months Among Patients With Acute Coronary Syndrome Receiving Loading Doses of Atorvastatin Prior to Planned PCIRenato D Lopes, Pedro G M de Barros E Silva, Lucas Petri Damiani, et al.
European Heart Journal. Acute Cardiovascular Care|March 3, 2020
Acute Cardiovascular Care Association position statement for the diagnosis and treatment of patients with acute myocardial infarction complicated by cardiogenic shock: A document of the Acute Cardiovascular Care Association of the European Society of CardiologyUwe Zeymer, Hector Bueno, Christopher B Granger, et al.
Journal of the American College of Cardiology|March 21, 2020
Oral Anticoagulation and Cardiovascular Outcomes in Patients With Atrial Fibrillation and End-Stage Renal DiseaseSean D Pokorney, Eric Black-Maier, Anne S Hellkamp, et al.
American Heart Journal|December 9, 2019
High-throughput targeted proteomics discovery approach and spontaneous reperfusion in ST-segment elevation myocardial infarctionJay S Shavadia, Christopher B Granger, Wendimagegn Alemayehu, et al.
American Heart Journal|November 2, 2013
Prognostic implications of left ventricular end-diastolic pressure during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Findings from the Assessment of Pexelizumab in Acute Myocardial Infarction studyAkshay Bagai, Paul W Armstrong, Amanda Stebbins, et al.
Circulation|December 8, 2004
Lessons learned from a clinical trialPaul W Armstrong, L Kristin Newby, Christopher B Granger, et al.
American Heart Journal|May 22, 2012
Variations in practice and outcomes in patients undergoing primary percutaneous coronary intervention in the United States and Canada: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI) trialRajendra H Mehta, Padma Kaul, Renato D Lopes, et al.
European Journal of Heart Failure|October 31, 2009
Adherence to medication according to sex and age in the CHARM programmeBradi B Granger, Inger Ekman, Christopher B Granger, et al.
JAMA|January 4, 2007
Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial, Paul W Armstrong, Christopher B Granger, et al.
Circulation|April 1, 2020
Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUSJohn H Alexander, Daniel Wojdyla, Amit N Vora, et al.
Pageof 91